-
Aug 16, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.
-
Aug 16, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 16, 2024Author(s):The expert panel explores the future landscape of lower-risk myelodysplastic syndrome treatment, considering recent approvals and emerging clinical data. Video content above is prompted by the followingWhat does the future of lower-risk MDS treatment look like? Following the latest approvals, guideline updates, and emerging data:How does this impact your future treatment strategies?
-
Aug 9, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 9, 2024Author(s):Medical professionals deliberate on patient selection criteria for second-line imetelstat treatment in lower-risk myelodysplastic syndromes, incorporating findings from the IMerge study into their considerations. Please comment on which patients you would consider 2L imetelstat for patients with LR-MDS. Please provide a summary of the IMerge study, evaluating imetelstat in patients that R/R to ESAs in LR-MDS. (Platzbecker U, Santini V, Fenaux P, et al. Lancet.
-
Aug 9, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 9, 2024Author(s):Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application. Focusing on real-world evidence (RWE), how do outcomes compare what’s seen in practice and how does that impact your choice of therapy? Real-world dose escalation and outcomes of luspatercept across all LOTs (Patel K, et al. EHA 2024.
-
Aug 2, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 2, 2024Author(s):Medical experts discuss sequencing strategies for second-line and later treatments in lower-risk myelodysplastic syndromes, examining how recent data, including insights from the MEDALIST trial, influence treatment selection and sequencing decisions. Let’s explore sequencing strategies for lower-risk MDS in the 2L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
-
Aug 2, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoAugust 2, 2024Author(s):Medical experts explore alternative treatment options for lower-risk myelodysplastic syndrome (LR-MDS) patients who are not suitable candidates for first-line luspatercept therapy. For patients who are not suitable to receive 1L luspatercept for LR-MDS, what alternate treatment options would you consider? What other trials on the horizon are you excited for in the 1L treatment of lower-risk MDS?
-
Jul 29, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoJuly 29, 2024Author(s):Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions. Briefly comment on the safety profile of available frontline treatments for patients with LR-MDS. How would you mitigate those events in your practice? How does toxicities observedimpact your overall treatment selection for patients?
-
Jul 29, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC
-
Jul 23, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoJuly 23, 2024Author(s):Experts in lower-risk myelodysplastic syndromes analyze and interpret the comparative biomarker data on ring sideroblasts in LR-MDS patients from the COMMANDS study. What insights can you share on the comparative biomarker analysis on RS in patients with LR-MDS from the COMMANDS study? Let’s continue our discussion by exploring real-world data and quality of life (QoL) findings in LR-MDS.
-
Jul 23, 2024 | 
onclive.com | Guillermo Garcia-Manero |Rami D. Komrokji |Esther Natalie Oliva |Amer M Zeidan |Thomas Cluzeau
OpinionVideoJuly 23, 2024Author(s):The panel examines the COMMANDS trial results, focusing on luspatercept's effects across erythroid, neutrophil, and platelet lineages and their implications for treatment decisions, while also exploring how genomic factors and mutational burden influence the drug's clinical outcomes in lower-risk myelodysplastic syndromes. How does the COMMANDS trial and outcomes on erythroid, neutrophil, and platelet lineages impact your treatment decision-making?
